Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861301 · ClinicalTrials.gov registry record · Phase 2
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01861301: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01861301 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01861301, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tivantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01861301
The ClinicalTrials.gov registry entry for NCT01861301 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01861301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01861301 about?
NCT01861301 is a clinical study titled "Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma". This phase II trial studies how well tivantinib works in treating patients with previously treated malignant mesothelioma. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01861301?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2013-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01861301?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tivantinib (DRUG).
Who is sponsoring clinical trial NCT01861301?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.